Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus NEOSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus NEOSPORIN.
BENSULFOID vs NEOSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Bensulfoid: not a recognized drug. No data available.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic